Strategic Wealth Partners Ltd. Has $2.06 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Strategic Wealth Partners Ltd. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 6.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,483 shares of the medical research company’s stock after selling 239 shares during the period. Strategic Wealth Partners Ltd.’s holdings in Thermo Fisher Scientific were worth $2,057,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Mystic Asset Management Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Advanced Research Investment Solutions LLC increased its stake in shares of Thermo Fisher Scientific by 213.3% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 47 shares of the medical research company’s stock worth $28,000 after acquiring an additional 32 shares in the last quarter. Lloyd Advisory Services LLC. increased its stake in shares of Thermo Fisher Scientific by 294.1% in the 1st quarter. Lloyd Advisory Services LLC. now owns 67 shares of the medical research company’s stock worth $40,000 after acquiring an additional 50 shares in the last quarter. Tyler Stone Wealth Management bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $47,000. Finally, Lansing Street Advisors bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $47,000. 86.50% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 0.3 %

Shares of Thermo Fisher Scientific stock opened at $558.13 on Thursday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 0.69. The firm has a market cap of $218.67 billion, a price-to-earnings ratio of 29.51, a price-to-earnings-growth ratio of 1.77 and a beta of 0.85. The business has a fifty day simple moving average of $568.24 and a 200-day simple moving average of $558.69. Thermo Fisher Scientific Inc. has a fifty-two week low of $497.83 and a fifty-two week high of $672.34.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, beating the consensus estimate of $4.92 by $0.59. The firm had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a return on equity of 24.36% and a net margin of 17.37%. Thermo Fisher Scientific’s quarterly revenue was up 18.3% on a year-over-year basis. During the same period in the previous year, the firm earned $5.60 earnings per share. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Thursday, September 15th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.22%. Thermo Fisher Scientific’s payout ratio is presently 6.39%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on TMO shares. Credit Suisse Group initiated coverage on shares of Thermo Fisher Scientific in a report on Wednesday, August 24th. They set a “neutral” rating and a $675.00 price target on the stock. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, July 29th. SVB Leerink boosted their target price on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. Finally, Barclays cut their price objective on shares of Thermo Fisher Scientific from $685.00 to $595.00 and set an “overweight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $655.64.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $588.36, for a total value of $5,883,600.00. Following the completion of the sale, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at approximately $107,889,338.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $588.36, for a total transaction of $5,883,600.00. Following the transaction, the chief executive officer now directly owns 183,373 shares in the company, valued at $107,889,338.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 12,300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $603.48, for a total value of $7,422,804.00. Following the completion of the sale, the chief financial officer now directly owns 43,944 shares in the company, valued at approximately $26,519,325.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,397 shares of company stock valued at $33,012,754. Corporate insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.